Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis
BACKGROUND: Prevalence and outcomes of coronavirus disease (COVID)-19 in relation to immunomodulatory medications are still unknown. The aim of the study is to investigate the impact of glucocorticoids and immunosuppressive agents on COVID-19 in a large cohort of patients with chronic immune-mediated inflammatory arthritis.
METHODS: The study was conducted in the arthritis outpatient clinic at two large academic hospitals in the COVID-19 most endemic area of Northern Italy (Lombardy). We circulated a cross-sectional survey exploring the prevalence of severe acute respiratory syndrome-coronavirus-2 nasopharyngeal swab positivity and the occurrence of acute respiratory illness (fever and/or cough and/or dyspnea), administered face-to-face or by phone to consecutive patients from 25 February to 20 April 2020. COVID-19 cases were defined as confirmed or highly suspicious according to the World Health Organization criteria. The impact of medications on COVID-19 development was evaluated.
RESULTS: The study population included 2050 adults with chronic inflammatory arthritis receiving glucocorticoids, conventional-synthetic (cs), or targeted-synthetic/biological (ts/b) disease-modifying drugs (DMARDs). Laboratory-confirmed COVID-19 and highly suspicious infection were recorded in 1.1% and 1.4% of the population, respectively. Treatment with glucocorticoids was independently associated with increased risk of COVID-19 (adjusted OR [95% CI] ranging from 1.23 [1.04-1.44] to 3.20 [1.97-5.18] depending on the definition used). Conversely, patients treated with ts/bDMARDs were at reduced risk (adjusted OR ranging from 0.46 [0.18-1.21] to 0.47 [0.46-0.48]). No independent effects of csDMARDs, age, sex, and comorbidities were observed.
CONCLUSIONS: During the COVID-19 outbreak, treatment with immunomodulatory medications appears safe. Conversely, glucocorticoids, even at low-dose, may confer increased risk of infection.
TRIAL REGISTRATION: Retrospectively registered. Not applicable.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
Arthritis research & therapy - 22(2020), 1 vom: 30. Dez., Seite 290 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Favalli, Ennio Giulio [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adrenal Cortex Hormones |
---|
Anmerkungen: |
Date Completed 14.01.2021 Date Revised 07.12.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s13075-020-02395-6 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM31944421X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM31944421X | ||
003 | DE-627 | ||
005 | 20231225171446.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s13075-020-02395-6 |2 doi | |
028 | 5 | 2 | |a pubmed24n1064.xml |
035 | |a (DE-627)NLM31944421X | ||
035 | |a (NLM)33380344 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Favalli, Ennio Giulio |e verfasserin |4 aut | |
245 | 1 | 0 | |a Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.01.2021 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: Prevalence and outcomes of coronavirus disease (COVID)-19 in relation to immunomodulatory medications are still unknown. The aim of the study is to investigate the impact of glucocorticoids and immunosuppressive agents on COVID-19 in a large cohort of patients with chronic immune-mediated inflammatory arthritis | ||
520 | |a METHODS: The study was conducted in the arthritis outpatient clinic at two large academic hospitals in the COVID-19 most endemic area of Northern Italy (Lombardy). We circulated a cross-sectional survey exploring the prevalence of severe acute respiratory syndrome-coronavirus-2 nasopharyngeal swab positivity and the occurrence of acute respiratory illness (fever and/or cough and/or dyspnea), administered face-to-face or by phone to consecutive patients from 25 February to 20 April 2020. COVID-19 cases were defined as confirmed or highly suspicious according to the World Health Organization criteria. The impact of medications on COVID-19 development was evaluated | ||
520 | |a RESULTS: The study population included 2050 adults with chronic inflammatory arthritis receiving glucocorticoids, conventional-synthetic (cs), or targeted-synthetic/biological (ts/b) disease-modifying drugs (DMARDs). Laboratory-confirmed COVID-19 and highly suspicious infection were recorded in 1.1% and 1.4% of the population, respectively. Treatment with glucocorticoids was independently associated with increased risk of COVID-19 (adjusted OR [95% CI] ranging from 1.23 [1.04-1.44] to 3.20 [1.97-5.18] depending on the definition used). Conversely, patients treated with ts/bDMARDs were at reduced risk (adjusted OR ranging from 0.46 [0.18-1.21] to 0.47 [0.46-0.48]). No independent effects of csDMARDs, age, sex, and comorbidities were observed | ||
520 | |a CONCLUSIONS: During the COVID-19 outbreak, treatment with immunomodulatory medications appears safe. Conversely, glucocorticoids, even at low-dose, may confer increased risk of infection | ||
520 | |a TRIAL REGISTRATION: Retrospectively registered. Not applicable | ||
650 | 4 | |a Clinical Trial | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Biologic drugs | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Glucocorticoids | |
650 | 4 | |a Rheumatic diseases | |
650 | 4 | |a SARS-CoV-2 | |
650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
650 | 7 | |a Antirheumatic Agents |2 NLM | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
700 | 1 | |a Bugatti, Serena |e verfasserin |4 aut | |
700 | 1 | |a Klersy, Catherine |e verfasserin |4 aut | |
700 | 1 | |a Biggioggero, Martina |e verfasserin |4 aut | |
700 | 1 | |a Rossi, Silvia |e verfasserin |4 aut | |
700 | 1 | |a De Lucia, Orazio |e verfasserin |4 aut | |
700 | 1 | |a Bobbio-Pallavicini, Francesca |e verfasserin |4 aut | |
700 | 1 | |a Murgo, Antonella |e verfasserin |4 aut | |
700 | 1 | |a Balduzzi, Silvia |e verfasserin |4 aut | |
700 | 1 | |a Caporali, Roberto |e verfasserin |4 aut | |
700 | 1 | |a Montecucco, Carlomaurizio |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Arthritis research & therapy |d 2003 |g 22(2020), 1 vom: 30. Dez., Seite 290 |w (DE-627)NLM124870457 |x 1478-6362 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2020 |g number:1 |g day:30 |g month:12 |g pages:290 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13075-020-02395-6 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 22 |j 2020 |e 1 |b 30 |c 12 |h 290 |